LOS ANGELES, Sept. 20, 2023 ~ Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, has announced that four abstracts have been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA.

The presentations include four posters: a Trials-in-Progress (TiP) update from the PRECISION1 trial in TSC1/2 alterations, two real-world clinical genomic analyses, and one preclinical study of nab-sirolimus combinations in breast cancer xenograft models.

The first poster is titled "Evaluation of nab-sirolimus in combination with PI3K pathway inhibitors to overcome PI3K/mTOR resistance in PI3K-mutant breast cancer cell lines". It will be presented by Sean Wallace, PhD; Khine Nyein Myint, PhD; Shihe Hou, PhD; Maria Zalath, BA; Andrew Kwon, PhD; Brian McMorran, PhD; and Igor Vivanco, PhD during Poster Session A on Thursday October 12th from 12:30 pm to 4:00 pm.

The second poster is titled "Phase 2 Multicenter Open Label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)". It will be presented by Candace Haddox MD; Gopa Iyer MD; Michael J. Demeure MD; Li Ding MS MA; Anita N. Schmid PhD; Willis H. Navarro MD; David J. Kwiatkowski MD PhD; Jordi Rodon Ahnert MD PhD during Poster Session B on Friday October 13th from 12:30 pm to 4:00 pm.

More on Boston Chron

• Mayor Wu Announces $1 Million in New Grant Funding to Support the Revitalization of Boston's Restaurant Industry
• Allotex Announces New Investor and Expansion of Production Facilities USA - English USA - English
• Green Office Partner Launches Managed Print Services Program in Canada
• GLCPS Sponsors Two Students to Attend Brown University Leadership Institute
• Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion

The third poster is titled "Real World Characterization and Frequency of TSC1 and/or TSC2 Alterations Collected from Tumor Tissue and Liquid Biopsies from the Tempus Genomic Database in Patients with Advanced Cancer". It will be presented by David J. Kwiatkowski MD PhD; Norma A Palma PhD; Willis H Navarro MD; Gopa Iyer MD during Poster Session B on Friday October 13th from 12:30 pm to 4:00 pm.

The fourth poster is titled "Inactivating TSC1 and TSC2 Alterations Co Mutations and Genomic Instability in Advanced Cancers Analysis of a Real World Patient Population Using the Foundation Medicine Genomic Database". It will be presented by David J Kwiatkowski MD PhD ; Norma A Palma PhD ; Willis H Navarro MD ; Gopa Iyer MD during Poster Session C on Saturday October 14th from 12:30 pm to 4:00 pm.

More information can be found on the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting website. Aadi Bioscience Inc., a biopharmaceutical company focused on developing precision therapies for patients with mTOR pathway alterations is proud to present these four abstracts at this prestigious conference.

---

Show All News | Report Violation